ABILIFY in DISKINEZIA TARDIVA

    Rajarethinam R et al. - The study supports our hypothesis that clinically stable patients with moderate tardive dyskinesia who are under treatment with other first- or second-generation antipsychotics may benefit from switching to aripiprazole with a reduction of TD symptoms but with out any significant benefit in psychiatric symptoms.

    Methods
    • Six clinically stable patients with schizophrenia or Schizoaffective disorder and a moderate to severe TD participated in this study.
    • They were systematically cross-titrated from their current medication to aripiprazole and maintained for 16 weeks.
    Results
    • The mean extra pyramidal symptom score measured by Abnormal Involuntary Movement Scale (AIMS) improved from a baseline score of 15.8 to final score of 5 (paired t-test; P=0.0009).
    • The severity of psychiatric symptoms remained unchanged

    No comments:

    Post a Comment